Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Scholar Rock Holding Corporation SRRK

Healthcare  —  Biotechnology
48.63 0.02 0.04% as of 25 Sep
Market cap
$6.0B
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Scholar Rock Holding Corporation (SRRK) Business Profile

Updated before January 2025

Company Overview

Scholar Rock Holding Corporation (NASDAQ: SRRK) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for serious diseases. Founded in 2012 and headquartered in Cambridge, Massachusetts, Scholar Rock focuses on targeting the molecular mechanisms of growth factors in the extracellular matrix. The company was co-founded by Timothy A. Springer, Ph.D., a renowned scientist and entrepreneur, along with other leading experts in the field of biology and drug development. Scholar Rock’s leadership team includes Nagesh Mahanthappa, Ph.D., MBA, who served as the founding CEO, and current CEO Tony Kingsley, who brings extensive experience in the biopharmaceutical industry. The company is supported by a strong board of directors and scientific advisors, ensuring a robust strategic direction.

Core Business Segments

Scholar Rock operates primarily in the biopharmaceutical sector, with a focus on developing therapies that modulate the activity of growth factors. The company’s core business segments include:

1. Muscle Disorders

Scholar Rock’s lead product candidate, apitegromab, is a monoclonal antibody designed to inhibit the activation of latent myostatin, a growth factor that negatively regulates muscle mass. Apitegromab is being developed for the treatment of spinal muscular atrophy (SMA), a rare genetic disorder characterized by muscle weakness and atrophy. The therapy has shown promising results in clinical trials, positioning it as a potential breakthrough treatment for SMA patients.

2. Fibrosis and Oncology

Scholar Rock is also advancing its pipeline in the areas of fibrosis and cancer. The company’s preclinical programs focus on targeting growth factors such as TGF-beta, which play a critical role in tissue fibrosis and tumor progression. These programs aim to address unmet medical needs in conditions such as idiopathic pulmonary fibrosis (IPF) and various cancers.

3. Platform Technology

Scholar Rock leverages its proprietary platform, Structural Biology and Drug Discovery, to identify and develop novel therapeutics. This platform enables the company to design highly specific inhibitors of growth factors, offering a unique approach to treating diseases driven by dysregulated growth factor activity.

Business Model

Scholar Rock’s business model is centered on innovation and strategic partnerships. The company generates revenue through collaborations with other biopharmaceutical companies, licensing agreements, and potential future product sales. Scholar Rock’s approach involves:

  • Research and Development (R&D): Investing heavily in R&D to advance its pipeline of product candidates.
  • Partnerships: Collaborating with industry leaders to accelerate the development and commercialization of its therapies.
  • Clinical Trials: Conducting rigorous clinical trials to demonstrate the safety and efficacy of its product candidates.
  • Regulatory Approvals: Navigating the regulatory landscape to bring its therapies to market.

Strategic Direction

Scholar Rock is committed to advancing its pipeline and expanding its therapeutic focus. Key strategic priorities include:

  • Advancing Apitegromab: Continuing the clinical development of apitegromab for SMA and exploring its potential in other muscle disorders.
  • Expanding the Pipeline: Developing new product candidates targeting growth factors involved in fibrosis, oncology, and other diseases.
  • Global Expansion: Establishing a presence in international markets to reach a broader patient population.
  • Sustainability Goals: Incorporating sustainable practices into its operations, including reducing its environmental footprint and promoting diversity and inclusion within the organization.

Competitive Landscape

Scholar Rock operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Biogen (BIIB): A leader in SMA treatments with its product Spinraza.
  • Roche (RHHBY): Developer of Evrysdi, another SMA therapy.
  • Regeneron Pharmaceuticals (REGN): Known for its expertise in monoclonal antibody therapies.
  • FibroGen (FGEN): Focused on fibrosis and oncology therapies.

Scholar Rock differentiates itself through its unique approach to targeting growth factors and its proprietary platform technology.

Risk Factors

Scholar Rock faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its product candidates.
  • Market Dependence: Reliance on the success of apitegromab and other pipeline products.
  • Competition: Intense competition from established players in the biopharmaceutical industry.
  • Supply Chain Disruptions: Potential challenges in sourcing raw materials and manufacturing its therapies.
  • Financial Risks: Dependence on external funding to support its R&D activities and operations.

Recent Developments

Scholar Rock has made significant progress in recent years, including:

  • Clinical Trial Advancements: Positive results from the Phase 2 TOPAZ trial of apitegromab in SMA patients.
  • Pipeline Expansion: Initiation of preclinical programs targeting TGF-beta in fibrosis and oncology.
  • Strategic Partnerships: Collaboration with leading biopharmaceutical companies to accelerate drug development.
  • COVID-19 Impact: Adjusting its operations to mitigate the impact of the pandemic on clinical trials and supply chains.

Investment Considerations

Strengths:

  • Innovative platform technology with broad therapeutic potential.
  • Promising clinical data for apitegromab in SMA.
  • Strong leadership team and scientific expertise.
  • Strategic partnerships and collaborations.

Risks:

  • High dependence on the success of apitegromab.
  • Regulatory and competitive challenges.
  • Financial risks associated with being a clinical-stage company.

Conclusion

Scholar Rock Holding Corporation is a pioneering biopharmaceutical company with a unique approach to targeting growth factors. With a promising pipeline, innovative platform technology, and a strong commitment to addressing unmet medical needs, Scholar Rock is well-positioned for future growth. However, investors should carefully consider the risks associated with investing in a clinical-stage company. As Scholar Rock continues to advance its pipeline and expand its therapeutic focus, it has the potential to make a significant impact on the lives of patients worldwide.